Related Experiment Video
Updated: Apr 13, 2026
07:13
Implantation of Tissue-Engineered Vascular Graft in Mouse Carotid Artery via Cuff Technique
Published on: May 2, 2025
995
Tissue-engineered acellular small diameter long-bypass grafts with neointima-inducing activity
Atsushi Mahara1, Shota Somekawa2, Naoki Kobayashi3
1Department of Biomedical Engineering, National Cerebral and Cardiovascular Center Research Institute, Fujishiro-dai, Suita, Osaka 565-8565, Japan.
Biomaterials
|May 6, 2015
Summary
Tissue-engineered vascular grafts show excellent patency in small-caliber bypasses. Modified ostrich arteries with REDV peptide prevented thrombosis, demonstrating a promising solution for artificial vascular grafts.
Area of Science:
- Biomaterials Science
- Vascular Surgery
- Tissue Engineering
Background:
- Small-caliber artificial vascular grafts remain unavailable due to challenges in achieving antithrombogenic surfaces.
- Developing effective vascular grafts is crucial for bypass surgeries.
Purpose of the Study:
- To demonstrate the patency of tissue-engineered small-caliber long-bypass grafts.
- To evaluate the antithrombogenic properties of modified ostrich arteries.
Main Methods:
- Modified acellular ostrich carotid arteries with a novel heterobifunctional peptide (collagen-binding region and REDV).
- Transplanted six modified grafts in a femoral-femoral artery crossover bypass model in animals.
- Observed grafts for 20 days without anticoagulant medication.
Main Results:
- Five out of six modified grafts demonstrated excellent patency.
- No thrombogenesis was observed on the luminal surface of modified grafts.
- All unmodified control grafts became occluded with severe thrombosis.
Conclusions:
- Tissue-engineered vascular grafts using modified ostrich arteries show short-term patency at clinically relevant sizes.
- The REDV peptide modification effectively creates an antithrombogenic surface.
- These findings represent a significant advancement in the development of artificial vascular grafts.
